Published online before print April 15, 2002, doi: 10.1161/01.CIR.0000015507.29953.38
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:2019.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Elevated C-Reactive Protein Values and Atherosclerosis in Sudden Coronary Death
Association With Different Pathologies
From the Department of Cardiovascular Pathology (A.P.B., R.K., R.V.), Armed Forces Institute of Pathology, Washington, DC; University of Vermont (R.B.T., F.K.), Burlington; Louisiana State University Health Science Center (G.T.M., A.Z.), New Orleans; and the University of Maryland (J.P., J.S.), Baltimore.
Correspondence to Renu Virmani, MD, Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000. E-mail virmani{at}afip.osd.mil
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Elevations in serum C-reactive protein measured by high-sensitivity assay (hs-CRP) have been associated with unstable coronary syndromes. There have been no autopsy studies correlating hs-CRP to fatal coronary artery disease.
Methods and Results— Postmortem sera from 302 autopsies of men and women without inflammatory conditions other than atherosclerosis were assayed for hs-CRP. There were 73 sudden deaths attributable to atherothrombi, 71 sudden coronary deaths with stable plaque, and 158 control cases (unnatural sudden deaths and noncardiac natural deaths without conditions known to elevate CRP). Atherothrombi were classified as plaque ruptures (n=55) and plaque erosion (n=18); plaque burden was estimated in each heart. Total cholesterol, high-density lipoprotein cholesterol, diabetes, smoking history, and body mass index were also determined. Immunohistochemical stains for CRP and numbers of thin cap atheromas per heart were quantitated in coronary deaths with hs-CRP in the highest and lowest quintiles. The median hs-CRP was 3.2 µg/mL in acute rupture, 2.9 µg/mL in plaque erosion, 2.5 µg/mL in stable plaque, and 1.4 µg/mL in controls. Mean log hs-CRP was higher in rupture (P<0.0001), erosion (P=0.005), and stable plaque (P=0.0003) versus controls. By multivariate analysis, atherothrombi (P=0.02), stable plaque (P=0.003), and plaque burden (P=0.03) were associated with log hs-CRP independent of age, sex, smoking, and body mass index. Mean staining intensity for CRP of macrophages and lipid core in plaques was significantly greater in cases with high hs-CRP than those with low CRP (P=0.0001), as were mean numbers of thin cap atheromas (P<0.0001).
Conclusions— hs-CRP is significantly elevated in patients dying suddenly with severe coronary artery disease, both with and without acute coronary thrombosis, and correlates with immunohistochemical staining intensity and numbers of thin cap atheroma.
Key Words: death, sudden • inflammation • protein, C-reactive • coronary disease • thrombosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
C-reactive protein (CRP), a member of the pentraxin family of proteins, is an acute-phase reactant, increasing 1000-fold in response to infection, ischemia, trauma, burns, and inflammatory conditions.1 Ligand-bound or aggregated CRP binds C1q and in so doing activates the classical complement pathway.2 Although primarily synthesized in the liver, there is evidence for local expression of CRP in macrophages of the lung and the brain.3–5 In atherosclerotic plaques, it has been found associated with complement proteins and within foam cells.6,7
A growing number of studies suggest that CRP is an independent risk factor for atherosclerotic vascular disease. Plasma CRP concentrations in the highest quartile are associated, depending on the subject group, with 1.5- to 7-fold increases in relative risk of symptomatic atherosclerosis.1,9 The baseline plasma concentration of C-reactive protein predicts the risk of future myocardial infarction and stroke10 and is associated with a poor prognosis in unstable angina.11–13
Elevations of CRP in acute coronary syndromes highlight the importance of inflammation in atherosclerotic lesions. There have been no morphological studies, however, correlating serum CRP levels with histopathological findings. In sudden coronary death, the mechanism of death is diverse. There may be acute coronary thrombosis attributable to acute plaque rupture, which is considered to be caused by inflammatory infiltration of a thin fibrous cap,14 or acute thrombus with plaque erosion, in which the role of inflammation is less clear,15 or there may be no thrombosis. The purpose of this study was to compare the serum levels of CRP in these types of sudden death with controls and to correlate serum CRP findings with immunohistochemical localization of CRP within plaques and numbers of thin cap atheromas (vulnerable plaques).
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Hearts were examined as previously described.16 Initial inclusion for study was any case of sudden unexpected death, natural or unnatural. For purposes of CRP category, these cases were classified on the basis of histological examination of internal viscera in addition to full autopsy data into 2 groups. The first group (n=302) included cases without known predisposing cause for elevations of CRP other than atherosclerosis and formed the final study. These were healthy control hearts without evidence of significant coronary disease (n=158), stable coronary atherosclerosis (
1 epicardial artery with 75% cross-sectional luminal narrowing in the absence of other causes of death or evidence of other processes known to elevate CRP, n=71), acute coronary thrombosis attributable to plaque rupture without myocardial necrosis (n=53), and coronary plaque erosion without myocardial necrosis (n=20). The second group (n=172), which was excluded for additional study, included cases with conditions known to elevate serum CRP other than atherosclerosis. These were 61 inflammatory conditions (15 bronchopneumonia, 5 infectious endocarditis, 5 sepsis, 4 pyelonephritis, 2 influenza, 1 staphylococcal mediastinitis, 7 hepatitis, 5 myocarditis, 5 pancreatitis, 4 sarcoidosis, 3 chronic prostatitis, 2 autoimmune disease, 2 colitis, and 1 inflammatory pseudotumor), 40 cases of congestive heart failure (left ventricular dilatation) in the presence of ischemia (healed infarct, n=15) or dilated cardiomyopathy (n=25), 33 cases of acute myocardial infarction with coronary disease, and 38 miscellaneous conditions (13 nonhepatitic liver disease, 11 trauma with survival >6 hours, 2 aortic dissection, 4 insulin-induced hypoglycemia, 4 deep venous thrombosis, 2 stroke, and 2 chronic dialysis).
In each case, coronary arteries were serially sectioned at 3- to 4-mm intervals, and all areas of 50% cross-sectional luminal narrowing were studied histologically. Acute thrombi were classified as plaque rupture or erosion, as previously described.15,17 Hearts were weighed to the nearest gram after removal of intracavity blood. Plaque burden was assessed in sudden coronary death and control cases and was calculated by adding the maximal percent cross-sectional area luminal narrowing in 4 arterial beds: left main, left anterior descending with diagonals, left circumflex with marginals, and right coronary with posterior descending artery (range, 0% to 400%). Thin cap atheromas (vulnerable plaques) were defined as a thin fibrous cap (<65-µm thick) infiltrated by macrophages and an underlying necrotic core, as previously described,16,18 and were counted in coronary cases with hsCRP in the highest (>3.2 µg/mL) and lowest (<1.0 µg/mL) quintiles. Risk factors were performed based on analysis of postmortem blood and sera as well as history and renal histological findings.16 A list of medications was available in most investigators’ reports; 2 women were known to be on hormone replacement therapy, and 121 additional patients were known to be taking over-the-counter or prescription medications not associated with elevations of CRP. C-reactive protein was measured using a high-sensitivity ELISA method, which has been used in variety of clinical studies.19–21 This assay has a coefficient of variation of 
5%. Levels of >3.0 µg/mL were considered elevated. There was no correlation between serum hs-CRP and postmortem interval in 123 cases without overt inflammation in which exact postmortem data were known (r2<0.001).
Immunohistochemical Stains
Sections of representative lesions of each major epicardial artery (left anterior descending, left circumflex, and right coronary artery) were randomly selected from 10 hearts with plaque erosion, 10 hearts with plaque rupture, and 10 hearts without coronary thrombi. Selection was based on 5 cases each with hsCRP in the highest and lowest quintiles. Immunohistochemical staining was carried out using standard avidin-biotin techniques and a commercially available antiserum for CRP (Sigma Corp) at a dilution of 1:200. Deparaffinized sections were incubated in 1 mmol/L EDTA buffer with steam heat before staining for antigen retrieval. Grading of staining intensity was assessed on macrophages and lipid core. A qualitative score of 0 to 4 was applied to each. Zero indicated no staining; 1+, <10% of macrophages staining or <10% of necrotic core area; 2+, 10% to 40% of macrophages staining or 10% to 40% of necrotic core area; 3+, 40% to 75% macrophages staining or 40% to 75% of necrotic core area; and 4+, >75% of necrotic core area or >75% macrophages staining. A sum of the 2 scores resulted in an overall grading system of 0 to 8.
Statistical Analysis and Serum Results
For comparison of serum hsCRP results among groups, log-normalized results for hsCRP were used because of the abnormal distribution of the data. Univariate associations between log hsCRP and glycohemoglobin, cholesterol, body mass index, and age were assessed by Student’s t test; univariate associations between log-hsCRP and smoking and sex were assessed by simple regression. Multivariate analyses were performed with 3 dependent variables separately: stable plaque (logistic regression), excluding acute thrombi; acute thrombi (logistic regression), excluding stable plaque; and plaque burden (linear regression), using all 302 cases. For multivariate analysis, age, body mass index, and sex were included as covariates.
Statistic Analysis, Immunohistochemical Staining, and Thin Cap Atheroma Quantitation
The mean CRP immunohistochemical staining score was compared among groups (high hsCRP, low hsCRP, erosion, rupture, and stable plaque) by ANOVA means table with Fisher’s post hoc test. Mean thin cap atheromas were compared between groups of highest and lowest hsCRP quintiles by Student’s t test.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The characteristics of the cases in group 1 are summarized in Table 1. The percentage of cases with elevated hsCRP increased from controls to atherosclerosis without and with thrombus. By univariate analysis, log hsCRP was significantly elevated in all groups versus controls. Although log hsCRP, percent of patients with elevated hsCRP, and median hsCRP were all higher in acute thrombi attributable to erosion or rupture compared with stable plaque, the differences between acute thrombosis and stable plaque were not statistically significant. Group 2 cases with conditions known to elevate hsCRP other than atherosclerosis showed significant elevations of hs-CRP that were greater than controls (P<0.0001). The median hsCRP was 9.6 µg/mL in patients with heart failure, 14.5 µg/mL in patients with acute myocardial infarction, and 27.3 µg/mL in inflammatory conditions and miscellaneous conditions known to elevate hsCRP.
|
Table 2 demonstrates characteristics of the groups, excluding cases of nonatherosclerotic causes for elevated hsCRP (group II). The mean age was significantly higher in cases with stable plaque compared with controls (P=0.0001), erosion, or rupture (P=0.02). Smoking frequency was elevated in those with thrombus attributable to rupture or erosion, total cholesterol was greatest in those with acute rupture, and body mass index was elevated in all atherosclerotic groups versus controls. In the 158 controls, age (r2=0.03, P=0.007) and body mass index (r2=0.04, P=0.005) were significantly associated with log hsCRP; log hsCRP was elevated in smokers (0.26±0.33) versus nonsmokers (0.16±0.30, P=0.03). There were no significant associations between log hsCRP and sex (0.20± 0.32, males; 0.18±0.29, females; P=0.8), glycohemoglobin (r2=0.01, P=0.15), total cholesterol (r2=0.01, P=0.23), or HDL-cholesterol (r2=0.01, P=0.08). There was a positive but statistically insignificant association between plaque burden and hs-CRP (r2 = 0.07, P<0.0001). Table 3 demonstrates an independent association between log hsCRP and stable plaque (P=0.03), acute thrombus (P=0.02), and plaque burden (P=0.03), after adjusting for age, sex, smoking, and body mass index in the linear regression models.
|
|
The overall staining score in the high hs-CRP group was 6.2±0.6 and in the low hs-CRP group was 2.9±0.5 (P=0.0001). The mean immunohistochemical score for arterial plaques in hearts with erosions was 4.5±0.9; for ruptures, 4.4±0.8; and for stable plaques, 4.8±0.9. There was no difference in CRP staining intensity between the 3 groups (P>0.5). The Figure demonstrates immunolocalization of CRP in tissue sections with a necrotic core and within macrophages. The mean numbers of thin cap atheromas was 0.95±0.22 in the low hs-CRP group and 3.0±0.3 in the high hs-CRP group of coronary deaths (P<0.0001).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
A relationship between unstable angina and elevated serum CRP levels was shown more than 10 years ago.22 More recently, it has been established that elevated serum CRP is associated with a poor prognosis in unstable angina patients13 and that it may predict future risk for myocardial infarction or stroke in apparently healthy men.10 It has been suggested that increased serum CRP, which is synthesized primarily in the liver in response to interleukin-6 and other cytokines, may not only be a marker of low level inflammation but may directly enhance inflammation in plaques.23,24 This amplification may be mediated by its involvement in binding to complement C1q when ligand bound or in an aggregate state and in activated endothelial cells with upregulation of chemokines and adhesion molecules.8,25
The present study demonstrates a modest elevation of serum hsCRP in autopsy samples of sudden coronary death, regardless of the apparent mechanism of death. There were significant elevations of serum hsCRP compared with controls in patients dying with acute coronary thrombi associated with plaque rupture or erosion as well as patients dying with stable plaque without evidence of thrombi. The present study also demonstrated (as expected) marked elevations of serum hsCRP in patients with acute myocardial necrosis and inflammatory conditions. These data in patients with myocardial infarction and inflammatory conditions were presented to validate the postmortem method of hsCRP measurement as well as highlight the increase in serum hsCRP that results with myocardial necrosis, which accompanies underlying coronary artery disease with thrombosis.
There have been several immunohistochemical studies demonstrating CRP within atherosclerotic plaques, primarily localized to macrophages and extracellularly within the lipid core.26–28 The present study is the first to correlate serum levels with histologic staining for CRP in fatal lesions. There was a positive correlation between the intensity of CRP staining with serum levels independent of mechanism of death (rupture, erosion, and stable plaque). In addition, the present study demonstrates a strong correlation between hsCRP levels and increased numbers of thin cap atheromas in the coronary tree. These results support the concept that hs-CRP in the serum reflects the numbers of atherosclerotic plaques with superficial foam cells and large necrotic cores and is correlated with local accumulation of CRP within the coronary lesions. The significance of this finding is unclear but suggests that the increased risk of patients with elevated serum hs-CRP in developing future coronary events lies in the increased numbers of plaque substrates (thin cap atheroma) prone to rupture.
The results of the present study suggest that hsCRP is a marker for coronary atherosclerosis, especially those lesions rich in lipid core and macrophages. Elevated serum levels of hsCRP were greatest in hearts harboring acute rupture and erosion. However, we were unable to demonstrate any significant increase or spike in serum hsCRP with lethal acute coronary thrombosis compared with patients dying with stable plaque. It is unclear whether the lack of significance is attributable to relatively small sample size or whether inflammatory mechanisms represent only a portion of the risk for developing fatal thrombosis. We have previously demonstrated that traditional risk factors such as smoking and hypercholesterolemia are independently associated with lethal coronary thrombi.16 Although hs-CRP is strongly related to the presence of thin cap atheromas, as the present study demonstrates, additional factors that may not be directly related to inflammation clearly play an important role in the subsequent development of occlusive fibrin platelet thrombi.
Clinical studies have suggested that although there is an association between elevations of hsCRP and acute coronary events, the link between plaque burden and hs-CRP is less clear. In the Cardiovascular Health Study and the Family Heart Study, there was little evidence of association between hsCRP and carotid artery wall thickness as assessed by ultrasound.29,30 In addition, imaging studies that measure correlates of plaque burden (ie, CT scans for calcification) failed to demonstrate a strong association between serum hsCRP and calcification.31,32 The present study demonstrates, however, that there is a significant association between coronary plaque burden and hs-CRP. The discrepancy among these results is unclear but likely related to the different methodologies used, because neither calcification nor carotid artery thickness directly measure coronary plaque composition. In addition, the correlation between plaque burden and hsCRP in the present study, although significant, was weak, with a low regression coefficient.
Most clinical studies have demonstrated an association between serum hsCRP and unstable coronary syndromes, independent of other risk factors. However, Doggen et al33 demonstrated in a case-control study that the effect of serum hsCRP on the risk of developing first acute myocardial infarction was greatly reduced if covariates of cholesterol, triglycerides, and high-density lipoprotein cholesterol were considered. In the present study, we found that the association of hsCRP with plaque burden and acute coronary thrombosis was lessened when covariates of glycohemoglobin and high-density lipoprotein were included in the analysis. This lessening is expected, because both hsCRP and glycohemoglobin are strongly associated with the metabolic syndrome and both hsCRP and HDL (negatively) are sensitive to inflammatory status. However, the effect of elevated hsCRP was significant to a similar degree to other measured risk factors, when risk for dying with stable plaque was considered. Therefore, despite relatively few cases, we observed a significant association of hsCRP with risk of dying from stable plaque, strengthening the role of hsCRP as a major risk factor for the development of clinical manifestations of coronary artery disease.
Limitations
Inherent limitations of the present study include the case-control nature of the autopsy study, the fact that controls included natural and unnatural deaths, and the fact that generalizations to other populations are impossible. In addition, methods of determining risk factors were limited to a single collection at postmortem, duration of risk factor exposure was generally not available, and information regarding risk factor modification (eg, aspirin, hormone replacement therapy, and statin use) was often incomplete.
Conclusion
This is the first autopsy study to corroborate the association between mild elevations of serum hs-CRP and coronary atherosclerosis. Specifically, elevated hs-CRP is associated with sudden death attributable to severe coronary disease, independent of the other risk factors most closely associated with hs-CRP, namely, age, smoking, and body mass index. The rise in hs-CRP was associated with thin cap atheromas and immunohistochemical deposition of CRP within plaques and, although higher in fatal thrombosis, was also elevated in patients dying with stable plaque. These results corroborate the concept that inflammation is an important component to plaque instability reflected by serum hs-CRP.
|
Acknowledgments |
|---|
This work was supported in part by research grants from the National Institutes of Health (RO1 HL61799 to Dr Virmani and HL46696 to Dr Tracy).
|
Footnotes |
|---|
Deceased. 
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.
Received December 7, 2001; revision received February 25, 2002; accepted February 25, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Westhuyzen J, Healy H. Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci. 2000; 30: 133–143.
2. Du Clos TW. Function of C-reactive protein. Ann Med. 2000; 32: 274–278.
3. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol. 1996; 156: 4815–4820.
4. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001; 69: 1747–1754.
5. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039–1051.
6. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20: 2094–2099.
7. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 2000; 10: 435–451.
8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165–2468.
9. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J. 1996; 312: 1061–1065.
10. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979.
11. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J. 2000; 140: 324–328.
12. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000; 35: 1535–1542.
13. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331: 417–424.
14. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657–671.
15. Farb A, Burke A, Tang A, et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996; 93: 1354–1363.
16. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in patients with coronary disease dying suddenly. N Engl J Med. 1997; 336: 1276–1282.
17. Farb A, Tang A, Burke A, et al. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995; 92: 1701–1709.
18. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262–1275.
19. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999; 45: 2136–2141.
20. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998; 97: 425–428.
21. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997; 43: 52–58.
22. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990; 65: 168–172.
23. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999; 100: 96–102.
24. Yeh TH, Anderson V, Pasceri V, et al. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001; 104: 974–975.
25. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001; 103: 2531–2534.
26. Hatanaka K, Li XA, Masuda K, et al. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995; 45: 635–641.
27. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987; 111: 265–269.
28. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998; 18: 1386–1392.
29. Tracy R, Macy E, Bovill E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17: 2167–2176.
30. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001; 88: 112–117.
31. Hunt ME, O’Malley PG, Vernalis MN, et al. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J. 2001; 141: 206–210.
32. Redberg RF, Rifai N, Gee L, et al. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol. 2000; 36: 39–43.
33. Doggen CJ, Berckmans RJ, Sturk A, et al. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med. 2000; 248: 406–414.
This article has been cited by other articles:
 |
|
 |
|
  S. Genovesi, M. G. Valsecchi, E. Rossi, D. Pogliani, I. Acquistapace, V. De Cristofaro, A. Stella, and A. Vincenti Sudden death and associated factors in a historical cohort of chronic haemodialysis patients Nephrol. Dial. Transplant., March 16, 2009; (2009) gfp104v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bogaty, L. Boyer, S. Simard, F. Dauwe, R. Dupuis, B. Verret, T. Huynh, F. Bertrand, G. R. Dagenais, and J. M. Brophy Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2339 - 2346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Wasserman, A. R. Sharrett, S. Lai, A. S. Gomes, M. Cushman, A. R. Folsom, D. E. Bild, R. A. Kronmal, S. Sinha, and D. A. Bluemke Risk Factor Associations With the Presence of a Lipid Core in Carotid Plaque of Asymptomatic Individuals Using High-Resolution MRI: The Multi-Ethnic Study of Atherosclerosis (MESA) Stroke, February 1, 2008; 39(2): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Blangy, N. Sadoul, B. Dousset, A. Radauceanu, R. Fay, E. Aliot, and F. Zannad Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction Europace, September 1, 2007; 9(9): 724 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Arbustini Total Erythrocyte Membrane Cholesterol: An Innocent New Marker or an Active Player in Acute Coronary Syndromes? J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2090 - 2092. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Norja, L. Nuutila, P. J Karhunen, and S. Goebeler C-reactive protein in vulnerable coronary plaques J. Clin. Pathol., May 1, 2007; 60(5): 545 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Lanza, D. Pitocco, E. P. Navarese, A. Sestito, G. A. Sgueglia, A. Manto, F. Infusino, T. Musella, G. Ghirlanda, and F. Crea Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade Eur. Heart J., April 1, 2007; 28(7): 814 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Kolodgie, A. P. Burke, K. S. Skorija, E. Ladich, R. Kutys, A. T. Makuria, and R. Virmani Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2523 - 2529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Minoguchi, T. Yokoe, A. Tanaka, S. Ohta, T. Hirano, G. Yoshino, C. P. O'Donnell, and M. Adachi Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur. Respir. J., August 1, 2006; 28(2): 378 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L M Biasucci, G Giubilato, G Biondi-Zoccai, T Sanna, G Liuzzo, M Piro, G De Martino, C Ierardi, A dello Russo, G Pelargonio, et al. C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator. Heart, August 1, 2006; 92(8): 1147 - 1148. [Full Text] [PDF]
|
|
|
|
|
|
K. Rahimi, S. Watzlawek, H. Thiele, M.-A. Secknus, B.-F. Hayerizadeh, J. Niebauer, and G. Schuler Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment Eur. Heart J., July 2, 2006; 27(14): 1706 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sangiorgi, A. Mauriello, E. Bonanno, C. Oxvig, C. A. Conover, M. Christiansen, S. Trimarchi, V. Rampoldi, D. R. Holmes Jr, R. S. Schwartz, et al. Pregnancy-Associated Plasma Protein-A Is Markedly Expressed by Monocyte-Macrophage Cells in Vulnerable and Ruptured Carotid Atherosclerotic Plaques: A Link Between Inflammation and Cerebrovascular Events J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2201 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Virmani, A. P. Burke, A. Farb, and F. D. Kolodgie Pathology of the vulnerable plaque. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C13 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Montero, J. Orbe, N. Varo, O. Beloqui, J. I. Monreal, J. A. Rodriguez, J. Diez, P. Libby, and J. A. Paramo C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells: Implications for Clinical and Subclinical Atherosclerosis J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1369 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Skowasch, S Schrempf, C J Preusse, J A Likungu, A Welz, B Luderitz, and G Bauriedel Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins Heart, April 1, 2006; 92(4): 495 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. -K. Yip, C. -H. Lu, C. -H. Yang, H. -W. Chang, W. -C. Hung, C. -I. Cheng, S. -M. Chen, and C. -J. Wu Levels and value of platelet activity in patients with severe internal carotid artery stenosis Neurology, March 28, 2006; 66(6): 804 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Meuwissen, A C van der Wal, H W M Niessen, K T Koch, R J de Winter, C M van der Loos, S Z H Rittersma, S A J Chamuleau, J G P Tijssen, A E Becker, et al. Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction J. Clin. Pathol., February 1, 2006; 59(2): 196 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. P. Liew and J. R Bartholomew Atheromatous embolization Vascular Medicine, November 1, 2005; 10(4): 309 - 326. [Abstract] [PDF]
|
|
|
|
|
|
S. De Servi, M. Mariani, G. Mariani, and A. Mazzone C-Reactive Protein Increase in Unstable Coronary Disease: Cause or Effect? J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1496 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Palmerini, A. Marzocchi, C. Marrozzini, P. Ortolani, F. Saia, L. Bacchi-Reggiani, S. Virzi, S. Gianstefani, and A. Branzi Preprocedural Levels of C-Reactive Protein and Leukocyte Counts Predict 9-Month Mortality After Coronary Angioplasty for the Treatment of Unprotected Left Main Coronary Artery Stenosis Circulation, October 11, 2005; 112(15): 2332 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Minoguchi, T. Yokoe, T. Tazaki, H. Minoguchi, A. Tanaka, N. Oda, S. Okada, S. Ohta, H. Naito, and M. Adachi Increased Carotid Intima-Media Thickness and Serum Inflammatory Markers in Obstructive Sleep Apnea Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Zieske, R. P. Tracy, C. A. McMahan, E. E. Herderick, S. Homma, G. T. Malcom, H. C. McGill Jr, J. P. Strong, and for the Pathobiological Determinants of Atheroscle Elevated Serum C-Reactive Protein Levels and Advanced Atherosclerosis in Youth Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1237 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tanaka, K. Shimada, T. Sano, M. Namba, T. Sakamoto, Y. Nishida, T. Kawarabayashi, D. Fukuda, and J. Yoshikawa Multiple Plaque Rupture and C-Reactive Protein in Acute Myocardial Infarction J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1594 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Sato, K Hatakeyama, A Yamashita, K Marutsuka, A Sumiyoshi, and Y Asada Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans Heart, April 1, 2005; 91(4): 526 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Venugopal, S. Devaraj, and I. Jialal Macrophage Conditioned Medium Induces the Expression of C-Reactive Protein in Human Aortic Endothelial Cells: Potential for Paracrine/Autocrine Effects Am. J. Pathol., April 1, 2005; 166(4): 1265 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-K. Yip, C.-L. Hang, C.-Y. Fang, Y.-K. Hsieh, C.-H. Yang, W.-C. Hung, and C.-J. Wu Level of High-Sensitivity C-Reactive Protein Is Predictive of 30-Day Outcomes in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention Chest, March 1, 2005; 127(3): 803 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F D Kolodgie, R Virmani, A P Burke, A Farb, D K Weber, R Kutys, A V Finn, and H K Gold Pathologic assessment of the vulnerable human coronary plaque Heart, December 1, 2004; 90(12): 1385 - 1391. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Stolle, B. Weitkamp, J. Rauterberg, S. Lorkowski, and P. Cullen Laser Microdissection-based Analysis of mRNA Expression in Human Coronary Arteries with Intimal Thickening J. Histochem. Cytochem., November 1, 2004; 52(11): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, C.-J. Wu, H.-W. Chang, C.-H. Yang, K.-H. Yeh, S. Chua, and M. Fu Levels and Values of Serum High-Sensitivity C-Reactive Protein Within 6 Hours After the Onset of Acute Myocardial Infarction Chest, November 1, 2004; 126(5): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Wisse The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2792 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zouridakis, P. Avanzas, R. Arroyo-Espliguero, S. Fredericks, and J. C. Kaski Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris Circulation, September 28, 2004; 110(13): 1747 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Miller, G. Rodgers, J. A. Charlesworth, B. Kirkland, S. R. Severson, T. E. Rasmussen, M. Yagubyan, J. C. Rodgers, F. R. Cockerill III, R. L. Folk, et al. Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1115 - H1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-K. Hong, G. S. Mintz, C. W. Lee, Y.-H. Kim, S.-W. Lee, J.-M. Song, K.-H. Han, D.-H. Kang, J.-K. Song, J.-J. Kim, et al. Comparison of Coronary Plaque Rupture Between Stable Angina and Acute Myocardial Infarction: A Three-Vessel Intravascular Ultrasound Study in 235 Patients Circulation, August 24, 2004; 110(8): 928 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. H. van Dielen, W. A. Buurman, M. Hadfoune, J. Nijhuis, and J. W. Greve Macrophage Inhibitory Factor, Plasminogen Activator Inhibitor-1, Other Acute Phase Proteins, and Inflammatory Mediators Normalize as a Result of Weight Loss in Morbidly Obese Subjects Treated with Gastric Restrictive Surgery J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4062 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Fruchart, M. C. Nierman, E. S. G. Stroes, J. J. P. Kastelein, and P. Duriez New Risk Factors for Atherosclerosis and Patient Risk Assessment Circulation, June 15, 2004; 109(23_suppl_1): III-15 - III-19. [Abstract] [Full Text]
|
|
|
|
|
|
D. Tousoulis, C. Pitsavos, C. Stefanadis, A. Tanaka, T. Sano, M. Namba, Y. Nishibori, Y. Nishida, T. Kawarabayashi, D. Fukuda, et al. C-Reactive Protein and Lesion Morphology * Response Circulation, March 9, 2004; 109 (9): e153 - e153. [Full Text] [PDF]
|
|
|
|
|
|
R. Arroyo-Espliguero, P. Avanzas, J. Cosin-Sales, G. Aldama, C. Pizzi, and J. C. Kaski C-reactive protein elevation and disease activity in patients with coronary artery disease Eur. Heart J., March 1, 2004; 25(5): 401 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonseca, C. Desouza, S. Asnani, and I. Jialal Nontraditional Risk Factors for Cardiovascular Disease in Diabetes Endocr. Rev., February 1, 2004; 25(1): 153 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. Williams, C. X. Zhang, B. A. Game, L. He, and Y. Huang C-Reactive Protein Stimulates MMP-1 Expression in U937 Histiocytes Through Fc{gamma}RII and Extracellular Signal-Regulated Kinase Pathway:: An Implication of CRP Involvement in Plaque Destabilization Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Engstrom, L. Stavenow, B. Hedblad, P. Lind, P. Tyden, L. Janzon, and F. Lindgarde Inflammation-Sensitive Plasma Proteins and Incidence of Myocardial Infarction in Men With Low Cardiovascular Risk Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2247 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Dalton, W. H. Hoffman, G. G. Passmore, and S. L. A. Martin Plasma C-Reactive Protein Levels in Severe Diabetic Ketoacidosis Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 435 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, S. J. Leslie, W. J. Sasiela, M. Szarek, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study Circulation, September 30, 2003; 108(13): 1560 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takano, K. Mizuno, S. Yokoyama, K. Seimiya, F. Ishibashi, K. Okamatsu, and R. Uemura Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy J. Am. Coll. Cardiol., August 20, 2003; 42(4): 680 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hognestad, K. Endresen, R. Wergeland, O. Stokke, O. Geiran, T. Holm, S. Simonsen, J. K. Kjekshus, and A. K. Andreassen Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients J. Am. Coll. Cardiol., August 6, 2003; 42(3): 477 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sano, A. Tanaka, M. Namba, Y. Nishibori, Y. Nishida, T. Kawarabayashi, D. Fukuda, K. Shimada, and J. Yoshikawa C-Reactive Protein and Lesion Morphology in Patients With Acute Myocardial Infarction Circulation, July 22, 2003; 108(3): 282 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Bashore and T. Gehrig Cholesterol emboli after invasive cardiac procedures J. Am. Coll. Cardiol., July 16, 2003; 42(2): 217 - 218. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Cao, C. Thach, T. A. Manolio, B. M. Psaty, L. H. Kuller, P. H.M. Chaves, J. F. Polak, K. Sutton-Tyrrell, D. M. Herrington, T. R. Price, et al. C-Reactive Protein, Carotid Intima-Media Thickness, and Incidence of Ischemic Stroke in the Elderly: The Cardiovascular Health Study Circulation, July 15, 2003; 108(2): 166 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.D. Stojanovic, P. Kwong, D.J. Byrne, A. Arnold, I.A. Jagroop, D. Nair, M. Press, S. Hurel, D.P. Mikhailidis, and G.M. Prelevic The Effects of Transdermal Estradiol Alone or with Cyclical Dydrogesterone on Markers of Cardiovascular Disease Risk in Postmenopausal Women with Type 2 Diabetes: A Pilot Study Angiology, July 1, 2003; 54(4): 391 - 399. [Abstract] [PDF]
|
|
|
|
|
|
W. Koenig C-reactive protein and cardiovascular risk: an update on what is going on in cardiology Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1039 - 1041. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Inflammation and Insulin Resistance Diabetes Care, May 1, 2003; 26(5): 1619 - 1623. [Full Text] [PDF]
|
|
|
|
|
|
T. Yokoe, K. Minoguchi, H. Matsuo, N. Oda, H. Minoguchi, G. Yoshino, T. Hirano, and M. Adachi Elevated Levels of C-Reactive Protein and Interleukin-6 in Patients With Obstructive Sleep Apnea Syndrome Are Decreased by Nasal Continuous Positive Airway Pressure Circulation, March 4, 2003; 107(8): 1129 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Monroe, R. A. Kerensky, E. Rivera, K. M. Smith, and C. J. Pepine Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 23S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt, E. J. Topol, I. Kushner, and A. Sehgal The Arterial Inflammation Hypothesis Arch Intern Med, October 28, 2002; 162(19): 2249 - 2251. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||